Insights
FDA & FTC compliance insights for healthcare marketing
Plain-English breakdowns of the warning letters, settlements, and regulatory shifts that determine whether your marketing can survive contact with a regulator.
Ketamine Clinic Marketing Compliance Guide: IV Ketamine for Depression Without Triggering an FDA Letter
Most ketamine clinic marketing problems are not exotic - they are six or seven repeated phrases that the FDA October 2023 communication and 2024 enforcement actions have already singled out. This guide focuses on the IV ketamine for depression use case and rewrites the patterns that get clinics in trouble.
NAD+ IV Therapy Marketing and the FDA Position: What Actually Has Approval, What Does Not, and How to Word It
Most NAD+ IV therapy marketing trouble is upstream of the FTC longevity-claim issue. It is the quiet implication that NAD+ has some kind of FDA status it does not have. Here is the actual FDA position and how to word a NAD+ program page around it.
Ozone Therapy Marketing Compliance Rules: The FDA Position on Medical Ozone and the Phrases That Trigger Action
The FDA has stated publicly that ozone is a toxic gas with no known useful medical application. That position is the entire frame for ozone therapy marketing. Most ozone clinic copy is written as if the FDA is silent on the topic - it is not.
BPC-157 Peptide Marketing and the 503A Pharmacy Layer: Why the FDA Bulks-List Decision Changed Everything
BPC-157 sits on the FDA category 2 list - nominated for 503A bulks and not advanced. Marketing copy written for the pre-category-2 era is now operating in a different legal world. Here is what changed and the rewrites that work.
TRT Marketing Compliance for Men's Health Clinics: The Hypogonadism Labeling Line and the Anti-Aging Trap
TRT has an FDA-approved indication: classical hypogonadism. Most men's health clinic marketing reads like the indication is feeling tired in your 40s. That gap is the entire compliance issue. Here is how to market TRT in 2026 without inheriting the anti-aging claim trap.
FDA Warning Letters at a 25-Year High: What Every Healthcare Practice Needs to Know in 2026
More than 200 FDA warning letters hit healthcare practices in 2024 - the highest volume in a quarter century. Here is what is being flagged, why regenerative medicine and med spas are on the front line, and what a defensible marketing program looks like now.
How a Single Social Media Post Can Become a Multi-Million-Dollar FTC Settlement
Multi-million-dollar FTC settlements against stem cell and regenerative medicine clinics now routinely start with a single Instagram caption or Facebook testimonial. Here is how that chain actually works - and the four places clinics lose control of it.
Structure/Function Claims vs. Disease Claims: The One FDA Distinction That Determines Whether Your Marketing Is Legal
One line separates legal marketing from a warning letter: the difference between a structure/function claim and a disease claim. Most practice owners think they know where the line is. They are usually wrong by one or two key phrases.
The 7 Banned Words That Trigger FDA Warning Letters in Healthcare Marketing (2026 Update)
Seven specific words generate a disproportionate share of FDA warning letters and FTC actions in healthcare marketing. Here is the 2026 list - with the compliant alternative for every word and five adjacent phrases that drag you into the same violation.
Stay ahead of enforcement
Scan your marketing before regulators do.
RegenCompliance checks every word of your clinic's marketing against live FDA and FTC enforcement data - and rewrites violations automatically.